Protocol No.: GS-US-528-6363

PURPOSE 4/HPTN 103: A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate the Pharmacokinetics and Safety of Twice Yearly Long-Acting Subcutaneous Lenacapavir for Pre-Exposure Prophylaxis in People Who Inject Drugs
Principal Investigator
Hodder, Sally
Phase
II
Age Group
Adult
Applicable Disease Site
Infectious Diseases
Participating Institutions
Health Sciences Center
West Virginia University
Contact
Lacey Kelley, RN
Research Nurse

View on ClinicalTrials.gov